BioHarvest Sciences
BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce nutraceutical and pharmaceutical compounds without traditional agriculture. It sells the VINIA red grape cell brand direct-to-consumers and offers contract development and manufacturing services to pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies worldwide.
- Company typePublic
- Founded2007
- HeadquartersVancouver, Canada
- Headcount51–100
- GTM typeB2B and B2C
- OfferingHardware or Manufacturing
What BioHarvest Sciences does
BioHarvest Sciences Inc. (Nasdaq: BHST), founded in 2007 in Israel by Dr. Yochi Hagay and Dr. Zaki Rakib and headquartered in Vancouver, Canada, operates a plant cell biology platform under two integrated business units. The proprietary Botanical Synthesis technology, marketed as Bio-Plant Cellicitation, grows plant cells in industrial bioreactors without cultivating the underlying plant, producing fingerprint-consistent, patentable compositions branded as Biologics+ with dramatically lower land, energy, and time inputs than traditional agriculture. The Direct-to-Consumer Products unit sells the VINIA family of red grape cell nutraceuticals (capsules, hydration drinks, functional coffee, tea, and chews) primarily through the Vinia.com subscription e-commerce platform and Amazon, reaching 85,000-90,000 active users at over 90% subscription mix. The CDMO Services unit, launched in March 2024, offers contract development and manufacturing to pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies, charging $2.5-3.0M in non-recurring engineering fees per multi-stage program while retaining ownership stakes and manufacturing royalties on successful compounds. Revenue in FY2025 reached $34.5M (37% YoY growth) with gross margins of 58-60% and Q4 2025 marking the first quarter of positive adjusted EBITDA ($0.5M). The company partners with Tate & Lyle for next-generation sweeteners, SaffronTech for saffron compounds, and a UAE-based fragrance group for rare scent compounds, while expanding into a new 80,000 square foot corporate campus in Yavneh, Israel. Following the April 2026 CEO transition in which co-founder Dr. Zaki Rakib assumed the CEO role, BioHarvest is positioned as a platform-plus-products biotech operating at the intersection of nutraceutical commercialization and contract development services.
BioHarvest Sciences firmographics
Firmographics- Name
- BioHarvest Sciences
- Legal name
- BioHarvest Sciences Inc.
- Website
- https://bioharvest.com
- Company type
- Public
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce nutraceutical and pharmaceutical compounds without traditional agriculture. It sells the VINIA red grape cell brand direct-to-consumers and offers contract development and manufacturing services to pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies worldwide.
- Ownership category
- akta.pro rank
BioHarvest Sciences industry classification
Industry- Product category
- Nutraceuticals & Botanical Ingredients
- NAICS
- Medicinal and Botanical Manufacturing (325411), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Biological Products, (No Disgnostic Substances) (2836)
- akta.pro primary industry
- Biologics (mAbs/Recombinant Proteins) CDMO (HLAGABAC)
- akta.pro secondary industries
- Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK), Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
Keywords
Where BioHarvest Sciences is headquartered
LocationHeadquarters
- HQ city
- Vancouver
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
BioHarvest Sciences business model
Business model- GTM type
- B2B and B2C
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Supply Chain, Operations, Marketing or Sales, Technology or R&D, Infrastructure
Revenue model
- Direct-to-Consumer (D2C) Products: BioHarvest generates revenue through proprietary nutraceutical products sold directly to consumers via e-commerce (Vinia.com) and Amazon. The flagship VINIA brand includes capsules, functional beverages (coffee, tea), hydration products, and chews. Revenue is subscription-based with over 90% of purchases being subscription, providing predictable recurring revenue. FY2025 revenues of $34.5 million with 37% year-over-year growth.
- CDMO Services: Contract Development and Manufacturing Organization services generating milestone-based revenue through staged development agreements. Partners pay Non-Recurring Engineering (NRE) costs of $2.5M-$3.0M for compound development. BioHarvest retains manufacturing royalties on successful compounds. The division targets pharmaceuticals, nutraceuticals, cosmeceuticals, and nutrition companies seeking novel plant-based compounds.
- Manufacturing Royalties: Royalty-driven revenue model from CDMO partnerships where BioHarvest earns manufacturing royalties on future compound production. Retains ownership stakes in developed compositions (e.g., 25% in saffron composition, 20% in fragrance compounds) and receives ongoing royalties from commercial production.
- VINIA Inside Ingredient Licensing: Licensing of proprietary VINIA Piceid resveratrol technology to food and beverage manufacturers for incorporation into consumer products. Tate & Lyle partnership represents the flagship example of this ingredient solutions model.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Monthly | VINIA subscription model with over 90% subscription-based purchases |
| Hybrid | Multi-year contract | CDMO Non-Recurring Engineering (NRE) costs ranging from $2.5M to $3.0M per development program |
Go-to-market motion2 records
Distribution channels5 records
Marketing channels7 records
BioHarvest Sciences product offering
Product offeringCore offering
BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce fingerprint-consistent, patentable plant-based compounds without growing the underlying plant. The company runs two business units: a Direct-to-Consumer product unit selling the VINIA line of red grape cell nutraceuticals (capsules, functional beverages, hydration drinks, and chews) primarily through subscriptions, and a Contract Development and Manufacturing Organization (CDMO) services unit that partners with pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies to develop novel plant-based molecules on a milestone and royalty basis.
Product overview
BioHarvest Sciences operates a platform-plus-products architecture centered on its proprietary Botanical Synthesis technology, which grows plant-based compounds without growing the underlying plant. The company serves two business verticals: a Direct-to-Consumer (D2C) Products business offering the VINIA family of nutraceutical products (capsules, hydration drinks, functional beverages, and chews), and a CDMO Services division providing contract development and manufacturing to pharmaceutical, nutraceutical, cosmeceutical, and nutrition partners. The core platform enables the creation of patentable botanical compositions while products like VINIA Blood Flow Hydration, VINIA Daily Chews, and VINIA SuperFood functional beverages extend the technology into consumer markets.
Differentiator
Problem solved
Functional benefit
Brands
- VINIA: Flagship red grape cell nutraceutical product containing the entire matrix of polyphenols including Piceid Resveratrol. The #1 Resveratrol Polyphenol Brand in the United States with over 85,000 active users.
- BIOLOGICS+
- VINIA Inside
- CDMO Services
Products and services
- VINIA Red Grape Cell Capsules Proprietary red grape cell nutraceutical capsules containing the entire matrix of polyphenols including Piceid Resveratrol. Designed to boost nitric oxide production and increase blood flow rate, supporting cardiovascular health, mental alertness, energy, and circulation for health-conscious consumers.
- VINIA Blood Flow Hydration First hydration formula powered by VINIA's blood flow technology, combining naturally sourced electrolytes with clinically studied red grape polyphenols to improve arterial dilation and enhance fluid delivery for active consumers.
- VINIA Daily Chews 2X Formula Chewable nutraceutical product with double-strength performance formula featuring VINIA red grape cell extract, designed to enhance blood flow and oxygen delivery for athletes and individuals with highly active lifestyles.
- VINIA Functional Superfood Coffee Functional coffee product line featuring VINIA Red Grape Superfood, designed to deliver blood flow benefits through daily coffee consumption.
- VINIA SuperFood Functional Tea Functional tea line infused with Piceid Resveratrol targeting the North American functional tea market, offering clinically supported blood flow benefits in a tea format.
- CDMO Services (Biologics+) Contract Development and Manufacturing Organization services leveraging the proprietary Botanical Synthesis platform, enabling pharmaceutical, nutraceutical, cosmeceutical, and nutrition industry partners to develop unique, patentable plant-based molecules with development timelines of 18-27 months and NRE costs of $2.5M-$3.0M paid by partner.
Quantifiable outcome
- 70% increase in arterial dilation after 12 weeks of daily VINIA consumption (clinical trial)
- +9 more outcomes
Companies that use BioHarvest Sciences
Customer profileNamed customers6 records
Segments5 records
Ideal customer profiles4 records
BioHarvest Sciences technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
BioHarvest Sciences partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered major, core and minor.
- UAE-based fragrance investment groupmajor$1.2 million Stage 2 contract for development of rare scent-producing plant compound for global fragrance industry. Multi-stage development program targeting $23 billion premium fragrance market. BioHarvest retains 20% ownership of successfully developed compositions and serves as manufacturing entity under royalty-driven model. Stage 2 project will produce material for commercial trials over six-to-nine months with production readiness targeted for H2 2027.
- SaffronTechcoreStrategic CDMO partnership to develop and commercialize saffron-derived botanical compounds using Botanical Synthesis technology. Addresses saffron supply constraints, cost, and environmental impact. Combines BioHarvest's bioreactor methods with Saffron Tech's saffron cultivation expertise. BioHarvest retained 25% ownership in developed saffron composition and earns manufacturing royalties. Stage 1 completed May 2026, advancing to Stage 2 valued at $1.125 million. Targets global saffron market estimated at nearly $500 million annually.
- Tate & Lyle PLCcoreFlagship partnership with global food ingredient leader Tate & Lyle to develop next-generation plant-based sweeteners using BioHarvest's Botanical Synthesis platform. Initial agreement signed December 2024, expanded in May 2026 to include multiple sweetener molecules targeting sugar reduction in food and beverage applications. Reflects strong technical progress and Tate & Lyle's ambition to equip manufacturers with flexible sweetening solutions. Tate & Lyle reported pro forma revenue of £2.12 billion for FY2025 following its acquisition of CP Kelco.
- Nasdaq-listed pharmaceutical companymajorCDMO contract with a Nasdaq-listed pharmaceutical company with an approved drug. First CDMO project to successfully complete Stage 1 and advance to Stage 2, validating the Botanical Synthesis platform for a variety of molecule types. Demonstrates platform capability for pharmaceutical applications.
- Royal Emerald PharmaceuticalsminorPartnership to supply disruptive cannabis solutions to companies conducting FDA-approved medical research. Provides cannabis compounds produced via Botanical Synthesis platform without growing the cannabis plant, addressing consistency and cleanliness challenges in the industry.
- SpaceTangominorFormal partnership with SpaceTango to explore effects of microgravity on plant cells and potential role of BioHarvest's technology supporting space travel and human settlements in space. Aligned with long-term sustainability vision including space applications.
- Batory FoodsminorFirst significant B2B VINIA sale in the US market announced December 2020. Batory Foods serves as a distribution channel for VINIA products to foodservice and ingredient customers.
Scale indicators34 records
Recent moves11 records
Expansion highlights6 records
BioHarvest Sciences competitors and assessment
Company assessmentMarket position
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
BioHarvest Sciences social profiles
Digital presenceBioHarvest Sciences compliance and trust
Trust signalCompliance1 record
BioHarvest Sciences financial estimates
Financial estimateRevenue estimate
Valuation estimate
BioHarvest Sciences leadership team
Management profileNumber of profiles
Profiles15 records
BioHarvest Sciences funding detail
Funding detailFunding overview
Funding rounds12 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
BioHarvest Sciences M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about BioHarvest Sciences
What does BioHarvest Sciences do?
BioHarvest Sciences operates a proprietary Botanical Synthesis platform that grows plant cells in bioreactors to produce fingerprint-consistent, patentable plant-based compounds without growing the underlying plant. The company runs two business units: a Direct-to-Consumer product unit selling the VINIA line of red grape cell nutraceuticals (capsules, functional beverages, hydration drinks, and chews) primarily through subscriptions, and a Contract Development and Manufacturing Organization (CDMO) services unit that partners with pharmaceutical, nutraceutical, cosmeceutical, and nutrition companies to develop novel plant-based molecules on a milestone and royalty basis.
Is BioHarvest Sciences a public or private company?
BioHarvest Sciences is a public company. It is classified as public and is currently operating.
When was BioHarvest Sciences founded?
BioHarvest Sciences was founded in 2007. It employs 51 to 100 people.
Where is BioHarvest Sciences based?
BioHarvest Sciences is headquartered in Vancouver, Canada, in the North America region.
How does BioHarvest Sciences make money?
Four revenue lines are on record. Direct-to-Consumer (D2C) Products are the primary driver. The others are CDMO Services, manufacturing Royalties and VINIA Inside Ingredient Licensing.
Does BioHarvest Sciences have an API?
No public API is recorded for BioHarvest Sciences.
What industry is BioHarvest Sciences in?
BioHarvest Sciences's product category is Nutraceuticals & Botanical Ingredients. Its primary akta.pro industry code is HLAGABAC, Biologics (mAbs/Recombinant Proteins) CDMO, with a secondary code of EUAAAIAK, Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives. Its NAICS code is 325411 and its SIC code is 2833.